Lacosamide Vivanta

Lacosamide, the active ingredient in Lacosamide Vivanta, is an anticonvulsant presented as an injectable solution for intravenous use. It treats partial‑onset seizures as adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamide Vivanta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an anticonvulsant used in the management of focal epileptic disorders. It is indicated for: - Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens in patients with epilepsy.

Lacosamide may cause a range of adverse reactions. Monitoring and patient education are essential.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Cardiac arrhythmia: including atrial fibrillation. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Suicidal ideation: new or worsening thoughts of self‑harm. - Respiratory depression: reduced breathing effort. - Anaphylaxis: acute allergic response requiring immediate medical attention.

Before initiating therapy, clinicians should consider several safety aspects. - Renal impairment: assess renal function and monitor for accumulation. - Cardiac conduction: obtain baseline ECG and observe for PR‑interval changes. - Concomitant CNS depressants: watch for additive sedation or respiratory effects. - Pregnancy: risk category unknown; use only if potential benefit justifies the risk. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with other medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., rifampin): may reduce lacosamide efficacy. - Other sodium‑channel blockers (e.g., phenytoin): risk of additive cardiac effects.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in hormonal efficacy. - Alcohol: may enhance central nervous system depression.